Back to top
more

AC Immune (ACIU)

(Delayed Data from NSDQ)

$2.35 USD

2.35
107,791

+0.06 (2.62%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $2.34 -0.01 (-0.43%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ACIU

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

AC Immune [ACIU]

Reports for Purchase

Showing records 41 - 60 ( 62 total )

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 41

10/14/2020

Daily Note

Pages: 4

TDP-43 an Emerging Target for Increasing Prevalence of Age-Related Dementia Beyond AD-Pipeline Implications

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 42

09/24/2020

Daily Note

Pages: 5

Superior Science and Entirety of Broad Pipeline Suggest Neurodegenerative Platform Here to Stay

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 43

08/06/2020

Company Report

Pages: 7

Anti-Tau Development Drives Pipeline Forward, 2H20 Readouts Forthcoming for Direction

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 44

07/17/2020

Daily Note

Pages: 4

Anti-Tau Vaccine Advancement Sets Stage for Year of Significant AD Readouts; Reit Buy and $11 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 45

07/09/2020

Daily Note

Pages: 4

Pipeline Diversified With Anti-Tau and Anti-Abeta Approaches, Multiple Readouts Can Drive 2020 Growth

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 46

05/05/2020

Company Report

Pages: 7

Anticipated Clinical Readouts Define 2020, Despite Context of Global Pandemic; Reit Buy and $11 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 47

04/01/2020

Company Report

Pages: 7

Amid Global Challenges, Neurodegenerative Platform Can Deliver With Foreseen 2020 Milestones

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 48

02/18/2020

Daily Note

Pages: 4

Our Comparative Thoughts on Crenezumab Development in Light of DIAN-TU Topline Disappointment; Reit Buy and $11 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 49

12/10/2019

Company Report

Pages: 7

Positive Outlook for Broad AD Pipeline Looking to 2020; Reit Buy and Raising PT to $11

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 50

08/15/2019

Company Report

Pages: 5

Incremental Pipeline Progress Towards the New Roadmap; Reit Buy and $8 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 51

07/12/2019

Daily Note

Pages: 5

Making Inroads Into Alzheimer’s Disease: Our Takeaways From the KOL Event on Down Syndrome

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 52

05/16/2019

Company Report

Pages: 5

Believe a Clear Roadmap May Guide the Way in the Labyrinth of Alzheimer’s Disease; Reit Buy and $8 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 53

02/04/2019

Company Report

Pages: 6

Our Thoughts on the Discontinuation of Crenezumab; Reit Buy and Lowering PT to $8

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 54

01/24/2019

Daily Note

Pages: 7

Zooming in on the Effector Function; Reit Buy and $18 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 55

12/13/2018

Daily Note

Pages: 3

Eli Lilly Deal Validates AC Immune’s Lead Position in Tau

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 56

11/13/2018

Industry Report

Pages: 6

An Update From 2018 CTAD: the Ever-expanding World of Alzheimer’s Disease (AD) Down the Rabbit Hole

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 57

11/09/2018

Daily Note

Pages: 6

Takeaways From AC Immune Key Opinion Leader (KOL) Event: Putting the Pieces Together

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 58

10/30/2018

Daily Note

Pages: 5

Incremental Data Update at CTAD Added Bricks to the Investment Story

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: AC Immune

Industry: Unclassified

Record: 59

08/09/2018

Company Report

Pages: 6

Latest Thoughts Following Quarterly Results

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: AC Immune

Industry: Unclassified

Record: 60

07/26/2018

Daily Note

Pages: 4

An Update of Crenezumab From AAIC 2018

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party